# Safety and Efficacy Study of TVGV-1 Vaccine to Treat HPV Induced Cervical HSIL

> **NCT02576561** · PHASE2 · UNKNOWN · sponsor: **THEVAX Genetics Vaccine** · enrollment: 10 (actual)

## Conditions studied

- Human Papillomavirus
- High-Grade Squamous Intraepithelial Lesions

## Interventions

- **BIOLOGICAL:** TVGV-1
- **BIOLOGICAL:** GPI-0100
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT02576561
- **Lead sponsor:** THEVAX Genetics Vaccine
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-11
- **Primary completion:** 2018-05
- **Final completion:** 2018-09
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2017-10-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02576561

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02576561, "Safety and Efficacy Study of TVGV-1 Vaccine to Treat HPV Induced Cervical HSIL". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02576561. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*